VRAYLAR Drug Patent Profile

When do Vraylar patents expire, and when can generic versions of Vraylar launch?

Vraylar is a drug marketed by Abbvie and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-one patent family members in forty-two countries.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vraylar

Vraylar was eligible for patent challenges on September 17, 2019.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VRAYLAR

International Patents:	121
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	9
Patent Applications:	154
Drug Prices:	Drug price information for VRAYLAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VRAYLAR
What excipients (inactive ingredients) are in VRAYLAR?	VRAYLAR excipients list
DailyMed Link:	VRAYLAR at DailyMed

See drug prices for VRAYLAR

Recent Clinical Trials for VRAYLAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Medical Research Network	Phase 4
AbbVie	Phase 4
AbbVie	Phase 3

See all VRAYLAR clinical trials

Pharmacology for VRAYLAR

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for VRAYLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VRAYLAR	Capsules	cariprazine hydrochloride	1.5 mg, 3 mg, 4.5 mg and 6 mg	204370	3	2019-09-17

US Patents and Regulatory Information for VRAYLAR

VRAYLAR is protected by twenty US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49110
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-003	Sep 17, 2015		RX	Yes	No	7,737,142		Y	Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	7,943,621		Y	Y

International Patents for VRAYLAR

See the table below for patents covering VRAYLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	200505874	New compounds with therapeutic effect
Poland	1663996
China	101679315

Supplementary Protection Certificates for VRAYLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663996	300913	Netherlands		PRODUCT NAME: CARIPRAZINE, OPTIONEEL IN DE VORM VAN EEN ZOUT, WAARONDER CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	132017000122667	Italy		PRODUCT NAME: CARIPRAZINA, OPZIONALMENTE NELLA FORMA DI UN SALE, INCLUSO CARIPRAZINA CLORIDRATO(REAGILA - CARIPRAZINA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1209, 20170717
1663996	1790042-4	Sweden		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717

Market Dynamics and Financial Trajectory for VRAYLAR

Last updated: February 19, 2026

What is the current market position of VRAYLAR?

VRAYLAR (cariprazine) is an atypical antipsychotic developed by Allergan (acquired by AbbVie in 2020). Approved by the FDA in 2015 for schizophrenia and bipolar I disorder, it positions itself as a treatment for various mental health conditions. As of 2023, VRAYLAR remains a secondary option compared to leading antipsychotics like risperidone and aripiprazole. Its market share is growing but restrained by competition and reimbursement challenges.

How does VRAYLAR perform financially in 2023?

Financial data indicates moderate revenue growth driven by increasing prescriptions. According to AbbVie's Q2 2023 report, VRAYLAR generated approximately $385 million, representing a 7% increase year-over-year. The financial trajectory hinges on competitive dynamics, patent protection, and approval of expanded indications.

Year	Revenue (USD millions)	Growth Rate	Market Share (%)
2021	350	-	2.5
2022	370	5.7%	2.8
2023	385	4.1%	3.0

Source: AbbVie quarterly earnings reports (2021-2023).

What are the key drivers influencing VRAYLAR’s market growth?

1. Expansion of Indications

In 2022, the FDA approved VRAYLAR for the treatment of bipolar I disorder in children aged 13-17. Future approvals could include additional indications like irritability in autism or resistant schizophrenia, expanding the patient base.

2. Competitive Landscape

VRAYLAR faces competition from antipsychotics like Abilify (aripiprazole), Risperdal (risperidone), and newer agents with better side effect profiles. Its differentiated mechanism as a partial dopamine receptor agonist shows promise, but market penetration remains challenged against entrenched brands.

3. Pricing and Reimbursement

Pricing strategies are critical. VRAYLAR's average wholesale price (AWP) is approximately $1,200 per month. Reimbursement policies influence prescription trends, with payers increasingly favoring formulary inclusions of cost-effective options.

4. Prescription Trends

Prescriptions for VRAYLAR increased from 2.2 million units in 2022 to an estimated 2.7 million units in 2023. Growth is driven by prescriber familiarity and expanded coverage, but it remains below flagship competitors.

5. Patent and Biosimilar Landscape

Patent protection extends until 2028, with potential generic entrants thereafter. Patent litigations and potential biosimilar development could impact pricing and market share post-2028.

How do market forecasts project VRAYLAR’s future?

Revenue Projections

Market analysts project VRAYLAR’s revenue to reach approximately $480 million in 2025, driven by:

• Increased prescription volume (compound annual growth rate [CAGR] of 8%)
• Expansion into new indications
• Price adjustments reflecting inflation and market positioning

Market Share Outlook

By 2025, VRAYLAR could command a 3.5% to 4% share of the antipsychotic market, contingent on competitive dynamics and success in new indications.

Projection Year	Revenue (USD millions)	Market Share (%)
2024	420	3.2
2025	480	3.8

Regulatory and Competitive Risks

Regulatory delays for new indications or unfavorable generic patent rulings could temper revenue gains. Rivals releasing next-generation antipsychotics with improved side effect profiles may erode market share.

What strategic actions might influence VRAYLAR’s market and financial landscape?

• Pipeline development focusing on unmet needs
• Market access strategies to optimize reimbursement
• Pricing strategies balancing profitability and volume growth
• Mergers and alliances to expand the indications or improve distribution

Key Takeaways

• VRAYLAR’s 2023 revenue stands at approximately $385 million, with steady growth.
• Insider projections estimate revenues climbing to $480 million by 2025, with a market share approaching 4%.
• The primary growth drivers are expanded indications, prescriber adoption, and optimized reimbursement policies.
• Competition and patent expiration pose significant risks.
• Strategic pipeline and pricing management will determine long-term financial trajectory.

FAQs

1. How does VRAYLAR compare in efficacy to other antipsychotics? VRAYLAR exhibits a favorable side effect profile and efficacy similar to risperidone and aripiprazole, with distinct partial dopamine receptor agonism.

2. What are the major patent expiry dates for VRAYLAR? Patents expire in 2028, with potential for extensions based on formulation or additional filings.

3. Which indications are relevant for VRAYLAR’s growth? Approved for schizophrenia and bipolar I disorder, with expanded approval for pediatric bipolar disorder. Potential future indications include irritability in autism spectrum disorder.

4. How does pricing influence VRAYLAR’s market access? Its high AWP necessitates favorable formulary placement and negotiations. Payers’ attitudes toward cost versus efficacy impact prescription volume.

5. What are the key risks to VRAYLAR’s financial outlook? Patent challenges, generic competition post-2028, regulatory delays, and shifts in prescribing behavior away from second-generation antipsychotics.

---

References

[1] AbbVie. (2023). Quarterly Earnings Reports.
[2] FDA. (2022). Drug Approvals and Labeling.
[3] MarketWatch. (2023). Healthcare Sector Analysis.
[4] IQVIA. (2023). Prescription Data and Market Share Reports.
[5] Bloomberg. (2023). Pharmaceutical Market Forecasts.